Table 1.
Demo-clinical background and outcomes of the Covid-19 patients in accordance with Remdesivir administration days
| Variables | RDSV administration days | Total n (%) | Significant “P” | |
|---|---|---|---|---|
|
| ||||
| Day1 - Day4 n (%) | Day 5 - Day7 n (%) | |||
| Age Group | ||||
| ≤59 years | 14 (32.6) | 29 (25.6) | 43 (21.1) | |
| ≥60 Years | 89 (55.5) | 72 (44.7) | 161 (78.9) | |
| Minimum age (Years) | 39 | 42 | 39 | |
| Maximum age (Years) | 87 | 94 | 94 | |
| Mean±SD (years) | 66±8.4 | 66.7±11.2 | 66.37±9.9 | χ2=7.009, “P”<0.05, Independent sample “t”=-0.463, “P”>0.05 |
| Gender | ||||
| Male | 45 (54.2) | 38 (45.8) | 83 (40.7) | χ2=0.777 |
| Female | 58 (47.9) | 63 (52.1) | 121 (59.3) | “P”>0.05 |
| Co-morbidity Status | ||||
| Hypertension and CVS[1]* | 16 (42.1) | 22 (57.9) | 38 (18.6) | “P”>0.05 |
| Diabetes & its complications | 53 (54.1) | 45 (45.9) | 98 (48) | |
| Chronic Respiratory disorder | 3 (37.5) | 5 (62.5) | 8 (3.9) | |
| Malignant disease | 1 (16.7) | 5 (83.3) | 6 (2.9) | |
| Connective tissue disorder and other | 7 (41.2) | 10 (58.8) | 17 (8.3) | |
| No Comorbidity | 23 (62.2) | 14 (37.8) | 37 (18.1) | |
| Covid-19 Vaccination status | ||||
| Yes | 8 (80) | 2 (20) | 10 (4.9) | “P”>0.05 |
| No | 95 (49) | 99 (51) | 194 (85.1) | |
| Mortality status | ||||
| Alive | 103 (50.5) | 101 (49.5) | 204 (100) | |
| Death | 0 (0) | 0 (0) | 0 (0) | |
| Total | 103 (50.5) | 101 (49.5) | 204 (100) | |
[1]Cardiovascular disorder including hypertension and its complications